Arquivos do dia: Maio 7, 2021
1/3 dos pacientes hospitalizados com COVID-19 apresentam alterações pulmonares depois de 1 ano.
7 Mai, 2021 | 10:51hComentários: One third of patients hospitalized with COVID-19 have lung changes after a year – University of Southampton E An integrated understanding of long-term sequelae after acute COVID-19 – The Lancet Respiratory Medicine
COVID-19 já causou 6,9 milhões de mortes ao redor do mundo, mais que o dobro demonstrado pelos relatórios oficiais.
7 Mai, 2021 | 10:50hComunicado de Imprensa: COVID-19 has caused 6.9 million deaths globally, more than double what official reports show – Institute for Health Metrics and Evaluation
Relatório: Estimation of total mortality due to COVID-19 – Institute for Health Metrics and Evaluation
Comentários: New analysis finds global Covid death toll is double official estimates – STAT E Global COVID-19 death toll more than double official estimates – IHME – Reuters
Estudo de coorte: Eventos arteriais, tromboembolismo venoso, trombocitopenia e sangramento após vacinação com Oxford-AstraZeneca ChAdOx1-S: 11 eventos tromboembólicos venosos em excesso por 100.000 vacinações; 2,5 tromboses venosas cerebrais em excesso por 100.000 vacinações.
7 Mai, 2021 | 10:48hEditorial: Thromboembolism and the Oxford-AstraZeneca vaccine – The BMJ
Comentários: Thrombosis and bleeding after the Oxford-AstraZeneca covid-19 vaccination – The BMJ Opinion E Putting risks into context: covid-19 vaccines and blood clots – The BMJ Opinion E Expert reaction to study from Denmark and Norway looking at rare blood clots after the Oxford-AstraZeneca vaccine – Science Media Centre
Comentário no Twitter
NEW research sheds more light on rate of rare blood clots after Oxford-AstraZeneca vaccine
Rate of adverse events low; benefits of the vaccine still outweigh risks in most situations, say researchershttps://t.co/LslgvzWlWi @Pottegard
— The BMJ (@bmj_latest) May 6, 2021
Opinião | Covid-19: vacina Sputnik decola, graças ao impulso da revista Lancet.
7 Mai, 2021 | 10:46hCovid-19: Sputnik vaccine rockets, thanks to Lancet boost – The BMJ
Comentário no Twitter
Journals risk being used in place of regulators when they publish studies of novel vaccines that have not yet been authorised by a major regulator @DoctorChrisVT unpicks the story of the Sputnik V vaccine https://t.co/lYf7l0lXcy
— The BMJ (@bmj_latest) May 6, 2021
O enigma COVID-19: decifrando a fisiopatologia e os fenótipos de uma nova doença.
7 Mai, 2021 | 10:44h
Comentário no Twitter
We forget that covid-19 is a new disease, never having been seen until late 2019, w/ different features than any prior illness. A truly outstanding review today on its pathophysiology https://t.co/8gx2w8r1xf @LancetRespirMed @osuchm and colleagues pic.twitter.com/WGIfI2nb9B
— Eric Topol (@EricTopol) May 6, 2021
Diretrizes Clínicas do CDC para diagnóstico e tratamento de botulismo, 2021.
7 Mai, 2021 | 10:43h
Comentário no Twitter
New CDC guidelines on botulism, the first botulism clinical guidelines are excellent.
🔑 points:
1) high clinical suspicion needed
2) BAT should be given in first 24 hours but can give later if progression of paralysis
3) Retreatment not recommended https://t.co/AfhrB74G0d— Joseph Marcus (@JosephMarcusID) May 7, 2021
Estudo randomizado: Monitoramento de tratamento farmacológico durante a indução de infliximabe não melhora a remissão da doença em pacientes com doenças inflamatórias crônicas imunomediadas.
7 Mai, 2021 | 10:42hEffect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial – JAMA (gratuito por tempo limitado)
Editorial: Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases – JAMA (gratuito por tempo limitado)
Comentário: Mixed Results with Refined Treatment Strategies for Rheumatic Diseases – Physician’s Weekly
Comentário no Twitter
Study findings do not support routine use of proactive therapeutic drug monitoring during infliximab induction for improving immune-mediated inflammatory disease remission rates https://t.co/sDslkVm3u9
— JAMA (@JAMA_current) May 5, 2021
Estudo randomizado: Entre pacientes com artrite reumatoide em remissão, a redução de DMARDs convencionais à metade da dose resultou em recorrência da doença em 25% dos pacientes, em comparação a 6% entre pacientes do grupo que manteve a dose padrão.
7 Mai, 2021 | 10:39hEffect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial – JAMA (gratuito por tempo limitado)
Editorial: Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases – JAMA (gratuito por tempo limitado)
Comentário: Mixed Results with Refined Treatment Strategies for Rheumatic Diseases – Physician’s Weekly
Estudo randomizado: A terapia profilática de feridas utilizando-se pressão negativa em incisão fechada reduz (diferença próxima de significância estatística; P = 0,06) o risco de infecção no local da cirurgia em mulheres obesas submetidas a parto cesariano.
7 Mai, 2021 | 10:37hRevisão: Quimioterapia intraperitoneal hipertérmica para câncer ovariano e câncer colorretal.
7 Mai, 2021 | 10:23hHyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer: A Review – JAMA Oncology (gratuito por tempo limitado)